Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference32 articles.
1. Bladder cancer incidence and mortality: a global overview and recent trends;Antoni;Eur. Urol.,2017
2. Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology;Spiess;J. Natl. Compr. Canc. Netw.,2017
3. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J. Clin. Oncol.,2000
4. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986;De Santis;J. Clin. Oncol.,2012
5. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J. Clin. Oncol.,2009
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience;Radiation Oncology;2024-06-16
2. Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience;2024-04-30
3. Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma;Current Oncology Reports;2024-04-11
4. Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology;Current Opinion in Urology;2024-02-29
5. The role of radiation therapy for de novo metastatic bladder and renal cancers;Cancer/Radiothérapie;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3